A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
- Author
- KANAI, Masashi1 ; OTSUKA, Yoshihiko2 ; MURAKAMI, Yoshiki7 ; IMAIZUMI, Atsushi2 ; CHIBA, Tsutomu1 6 ; NISHIHIRA, Jun4 ; SHIBATA, Hiroyuki3 ; OTSUKA, Kazunori3 ; SATO, Maremi4 ; NISHIMURA, Takafumi1 ; MORI, Yukiko1 ; KAWAGUCHI, Michiya5 ; HATANO, Etsuro5 ; KODAMA, Yuzo6 ; MATSUMOTO, Shigemi1
[1] Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
[2] Theravalues Corporation, Tokyo, Japan
[3] Department of Clinical Oncology, Akita University Graduate School of Medicine, Akita, Japan
[4] Department of Medical Management and Informatics, Hokkaido Information University, Hokkaido, Japan
[5] Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
[6] Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
[7] Department of Hepatology, Osaka City University Hospital, Osaka, Japan - Source
Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 6, pp 1521-1530, 10 p ; ref : 43 ref
- CODEN
- CCPHDZ
- ISSN
- 0344-5704
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Bioavailability Curcumin Gemcitabine Pancreatic cancer Theracurmin®
- Keyword (fr)
- Anticancéreux Biodisponibilité Cancer du pancréas Curcumine Essai clinique phase I Gemcitabine Homme Pharmacocinétique Polyphénol Toxicité Traitement Tumeur maligne Antimétabolite Cancer Dérivé de la pyrimidine Fluor Composé organique Inhibiteur de la tyrosine kinase Pathologie de l'appareil digestif Pathologie du pancréas Phénols Pyrimidine nucléoside
- Keyword (en)
- Antineoplastic agent Bioavailability Pancreas cancer Curcumin Phase I trial Gemcitabine Human Pharmacokinetics Polyphenol Toxicity Treatment Malignant tumor Antimetabolic Cancer Pyrimidine derivatives Fluorine Organic compounds Tyrosine kinase inhibitor Digestive diseases Pancreatic disease Phenols Pyrimidine nucleoside
- Keyword (es)
- Anticanceroso Biodisponibilidad Cáncer del páncreas Curcumina Ensayo clínico fase I Gemcitabina Hombre Farmacocinética Polifenol Toxicidad Tratamiento Tumor maligno Antimetabólito Cáncer Pirimidina derivado Fluor Compuesto orgánico Inhibidor tyrosine kinase Aparato digestivo patología Páncreas patología Fenoles Pirimidina nucleósido
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27614515
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00280-013-2151-8 
https://dx.doi.org/10.1007/s00280-013-2151-8
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-013-2151-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1521\";s:8:\"\u0000*\u0000epage\";s:4:\"1530\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"OTSUKA, Yoshihiko\";i:1;s:17:\"MURAKAMI, Yoshiki\";i:2;s:17:\"IMAIZUMI, Atsushi\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"NISHIHIRA, Jun\";i:5;s:17:\"SHIBATA, Hiroyuki\";i:6;s:16:\"OTSUKA, Kazunori\";i:7;s:12:\"SATO, Maremi\";i:8;s:19:\"NISHIMURA, Takafumi\";i:9;s:12:\"MORI, Yukiko\";i:10;s:18:\"KAWAGUCHI, Michiya\";i:11;s:14:\"HATANO, Etsuro\";i:12;s:12:\"KODAMA, Yuzo\";i:13;s:18:\"MATSUMOTO, Shigemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-013-2151-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1521\";s:8:\"\u0000*\u0000epage\";s:4:\"1530\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"OTSUKA, Yoshihiko\";i:1;s:17:\"MURAKAMI, Yoshiki\";i:2;s:17:\"IMAIZUMI, Atsushi\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"NISHIHIRA, Jun\";i:5;s:17:\"SHIBATA, Hiroyuki\";i:6;s:16:\"OTSUKA, Kazunori\";i:7;s:12:\"SATO, Maremi\";i:8;s:19:\"NISHIMURA, Takafumi\";i:9;s:12:\"MORI, Yukiko\";i:10;s:18:\"KAWAGUCHI, Michiya\";i:11;s:14:\"HATANO, Etsuro\";i:12;s:12:\"KODAMA, Yuzo\";i:13;s:18:\"MATSUMOTO, Shigemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-013-2151-8\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-013-2151-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1521\";s:8:\"\u0000*\u0000epage\";s:4:\"1530\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"OTSUKA, Yoshihiko\";i:1;s:17:\"MURAKAMI, Yoshiki\";i:2;s:17:\"IMAIZUMI, Atsushi\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"NISHIHIRA, Jun\";i:5;s:17:\"SHIBATA, Hiroyuki\";i:6;s:16:\"OTSUKA, Kazunori\";i:7;s:12:\"SATO, Maremi\";i:8;s:19:\"NISHIMURA, Takafumi\";i:9;s:12:\"MORI, Yukiko\";i:10;s:18:\"KAWAGUCHI, Michiya\";i:11;s:14:\"HATANO, Etsuro\";i:12;s:12:\"KODAMA, Yuzo\";i:13;s:18:\"MATSUMOTO, Shigemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-013-2151-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1521\";s:8:\"\u0000*\u0000epage\";s:4:\"1530\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"OTSUKA, Yoshihiko\";i:1;s:17:\"MURAKAMI, Yoshiki\";i:2;s:17:\"IMAIZUMI, Atsushi\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"NISHIHIRA, Jun\";i:5;s:17:\"SHIBATA, Hiroyuki\";i:6;s:16:\"OTSUKA, Kazunori\";i:7;s:12:\"SATO, Maremi\";i:8;s:19:\"NISHIMURA, Takafumi\";i:9;s:12:\"MORI, Yukiko\";i:10;s:18:\"KAWAGUCHI, Michiya\";i:11;s:14:\"HATANO, Etsuro\";i:12;s:12:\"KODAMA, Yuzo\";i:13;s:18:\"MATSUMOTO, Shigemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-013-2151-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1521\";s:8:\"\u0000*\u0000epage\";s:4:\"1530\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:17:\"OTSUKA, Yoshihiko\";i:1;s:17:\"MURAKAMI, Yoshiki\";i:2;s:17:\"IMAIZUMI, Atsushi\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"NISHIHIRA, Jun\";i:5;s:17:\"SHIBATA, Hiroyuki\";i:6;s:16:\"OTSUKA, Kazunori\";i:7;s:12:\"SATO, Maremi\";i:8;s:19:\"NISHIMURA, Takafumi\";i:9;s:12:\"MORI, Yukiko\";i:10;s:18:\"KAWAGUCHI, Michiya\";i:11;s:14:\"HATANO, Etsuro\";i:12;s:12:\"KODAMA, Yuzo\";i:13;s:18:\"MATSUMOTO, Shigemi\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:128:\"A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin\u00ae) in cancer patients\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
